
Index

A

- Adiponectin, 853, 855
 - chondrogenesis and osteoblastogenesis, 865–868
 - concentration, 857
 - effects in osteoporosis, 861
 - interaction, 860
 - regulatory factors, 862–868
 - structure, 857
- AdipoR1, 855, 856, 865, 867, 868
- AdipoR2, 852, 855, 857, 865, 870, 875
- Adolescent, 75, 79, 82, 94
- Advanced glycation end products (AGEs), 359, 410, 412–415
- Age-related diseases, 1036
- Alkaline phosphate, 890–898, 937
- Alveolar bone, 282, 292, 294, 295
- Ameloblastin
 - as bone site-specific marker, 288
 - bone site-specific molecular fingerprint, 289–290
 - and craniofacial bone healing, 290–291
 - and embryonic origin, 290
 - expression in incisor/parodontium complex, 285
 - expression, 277, 282–283
 - functions and pathways, 284–288
 - gene and proteins, 281
 - and jaw bone biomechanical responsiveness and plasticity, 291–293
 - in jaw bone reconstruction, 296
- Amelogenesis, 273–275
- Amelogenin, 277
- Amino PTH (N-PTH), 141
- Antioxidant, 204–206
- Antiretroviral therapy
 - and HIV infection, 761, 762
 - initiation, 763

- medications, 772
 - uses, 762
- Articular cartilage, 1002
 - Autoimmune diseases, 400, 402

B

- Bariatric surgery, 740, 744, 745, 747, 749
- Biochemical marker(s), 743, 745, 747, 973–974
 - ADO II, 476–481
 - bone turnover in IUGR, 787–790
 - CLCN7, 471–472
 - pregnancy-induced hypertension, 823–827
- Biomarker(s), 115, 684, 685, 912, 916, 920–921, 1052, 1094–1096
 - bone formation markers, 8–9
 - for bone resorption and formation, 365–367
 - bone resorption markers, 9–12
 - circulating osteosarcoma, 40
 - collagen biomarkers, 999–1009
 - non-collagenous biomarkers, 1009–1013
 - for osteoarthritis (*see* Osteoarthritis)
 - osteosarcoma cells, 35–39
 - osteosarcoma tissues, 39
- Bisphosphonate(s), 188
 - genetic factors, 1078
 - postmenopausal osteoporosis, 1070
 - suboptimal response, 1071
- Bone, 132, 139, 141, 333
 - biomarkers, 757, 765, 770
 - density, 90
 - development, 703, 705
 - disease, 8, 50, 307–308
 - formation, 51, 561, 563, 564, 566, 578, 727, 729, 730, 732, 1047, 1049, 1051
 - formation markers, 8–9
 - fracture, 208, 213–215
 - geometry, 626, 632, 634, 638

- Bone (*cont.*)
- loss markers, 51
 - markers, 50
 - mass, 725, 731
 - metastasis, 260
 - parathyroid hormone in, 449
 - pentraxin, 3, 257
 - role in osteoarthritis, 996
 - strength, 625–626, 639–640
 - texture, 592, 594
- Bone marker(s), 242, 244, 917
- bone formation markers, 78–79
 - bone resorption markers, 82
 - bone studies, 684
 - carbonate substitution rate, 683
 - in clinical trials, 1013
 - collagen maturity and cross linking, 683
 - crystallinity, 682
 - joint analysis and other tissue, 692
 - mineral to matrix ratio, 682
 - reference values, 82
- Bone marrow density (BMD), 536–539
- Bone marrow lesions (BML), 535
- Bone metabolism, 79, 396, 398, 401, 806, 815
- bone formation markers, 8–9, 78–79
 - bone resorption markers, 9–12, 81–82
 - calcium and phosphate regulation, 13
 - cortisol, 15–16
 - cytokines, 18
 - estrogens, 14
 - fibroblast growth factors, 16
 - insulin, 16
 - insulin-like growth factors (IGF, type I and II), 17
 - parathyroid and calcium, 12
 - parathyroid hormone and calcitonin, 12
 - prostaglandins, 17
 - testosterone, 14
 - thyroid hormones, 13
 - transforming growth factors (TGF β 1 and β 2), 17
 - vitamin D, 14–15
- Bone mineral density, 207–213, 512, 515, 519, 909, 961, 986, 1071, 1074–1075, 1097–1099, 1133, 1138
- pregnancy-induced hypertension, 822–823
- Bone morphogenetic protein (BMP), 940–941
- Bone quality, 363, 410, 417, 418, 673
- Bone regeneration, 272, 291, 293, 295
- Bone remodeling, 271, 282, 293–296, 332, 334, 741–743, 909, 917, 927, 936, 947, 950, 1049–1050
- Bone resorption, 561, 564, 565, 567, 728, 732
- markers, 9–12
 - TRACP, 428–431
- Bone specific alkaline phosphatase (BAP), 729
- physiologic decrease, 1052
 - physiologic increases, 1051
 - as prognostic factor, 1059
- Bone turnover, 445, 452, 453, 561, 564–565, 572–581, 821, 823, 1051, 1111–1112
- application of markers to prognosis, 986
 - biochemical markers, 973–974
 - definition, 1067
 - in diabetes, 1116–1117
 - factors affecting, 977–979
 - glucose intake, 1113–1116
 - hormone effects on, 979–986
 - marker(s), 1072–1077
 - pathophysiology, 972
- Bone turnover markers, 365, 909–910, 936–939, 1111–1112
- in diabetes, 1116–1117
 - in fetus/neonate, 786–787
 - and glucose, 1113–1116
 - in IUGR, 787–790
- Bone-related proteins
- age-related diseases, 1036
 - in atherosclerosis and vascular remodeling, 1034–1036
 - biological role, 1029
 - description, 1028
 - in heart failure, 1037–1038
 - in stroke, 1037
- Books, 1175
- Breast cancer, 400
- C**
- Calcium (Ca), 448, 454, 456, 802
- Carboxymethyl-lysine (CML), 410
- Cardiovascular disease(s), 205–206, 400, 1026, 1035, 1176
- Cartilage, 835, 836, 838
- Cartilage degradation, 650
- Cell surface glycoproteins, 650
- CHI3L1, 311, 313, 315, 317, 320
- Children, 242, 244
- CHIT1, 311, 313, 317, 319
- in osteolytic process, 314–318
- Chondrocyte differentiation, 650, 654, 666
- Chronic kidney disease, 130
- CLCN7, 471–473
- Cohort studies, 93, 94
- Collagen, 334, 340, 343, 493–495, 920, 921

biomarkers, 999–1009
maturity, 683
type, 1, 185, 188
Computed tomography (CT), 538, 546
CR-39 detector, 111, 113, 118
Creatine kinase, 181
 function, 183
 isoforms, 182, 184
 structures, 183
Creatine kinase isoforms, 183, 184, 192, 194
Crystallinity, 682
C-terminal telopeptide cross links (CTX), 728, 729
C-terminal type I collagen telopeptide, 938

D

Daidzein, 1138, 1143
Diabetes mellitus, 400, 402, 1110
Dual-energy x-ray absorptiometry (DXA), 590, 628, 630, 631, 636, 639

E

Early nutrition, 711
Enamel matrix, 273–275
Enamel protein
 in mineralizing enamel, 275–276
 outside the enamel tissue, 276–281
Environmental radionuclides, 109
Evidence, 1173, 1175
Excretion, 805, 806, 808, 812
Exercise, 1050–1051
 BAP fluctuations by, 1051–1052
 long term effects, 1055–1059
 short term effects, 1052–1055

F

Fetus/neonate
 bone turnover markers, 786–787
Finite element analysis (FEA), 626, 630, 639–640
Formation, 998
Fracture, 75, 590, 592, 593, 597, 599, 600, 605–608, 759, 773, 1100
 atypical femoral, 1081
 fragility, 1067, 1070, 1079
 risk, 360, 631–634, 1075
 risk factor, 1073, 1075
 in women, 1073

G

Gamma-ray, 110, 122
Genistein, 1133, 1136
Gestational hypertension. *See* Pregnancy-induced hypertension
Glucocorticoid
 availability, 908
 hyperparathyroidism caused by, 918
 mechanisms of action, 909
 osteoporosis treatment, 922–927
 preparations of, 908
 routes of administration, 908
 therapy on bone turnover markers, 918–920
Glucose
 and bone turnover markers, 1113–1116
 and diabetic bone disease, 1123–1125
 on mesenchymal stem cells, 1122
 on osteoclasts, 1117, 1121
 on osteocytes, 1121
Glycoblotting method
 glycome profiling, 652–654
 N-glycan profiling, chondrogenic differentiation of ATDC5 cells, 654–661
Glycoform-focused reverse proteomics and genomics, 662
Glycomics, 651, 653, 661, 666
Growth, 75, 77, 78, 725, 731

H

Health-related quality of life (HRQoL), 1159, 1163, 1165
High bone mass, 231
Hip axis length (HAL), 633, 635, 636
Hip fracture(s), 408, 410, 412–415
 assessment of, 1159, 1162
 and biomarkers, 1163
 categories of, 1163
 incidence, 1159
 interventions, 1165
 outcome, 1159
Human immunodeficiency virus (HIV), 757
 bone measurement, 759–760
 in children, 772
 drugs, 763–769
 early, 771
 impact of treatment, 762–763
 low bone density, 758
 in older patients, 772
 osteomalacia, 775
 osteonecrosis, 775
 prevention, 769–771

- Human immunodeficiency virus (HIV) (*cont.*)
 switching therapy, 774
 in women, 771
- 3-Hydroxy-3-methylglutaryl coenzyme a
 (HMG-CoA) reductase inhibitors, 938
- Hyperglycemia, 1116, 1120, 1124
- Hypermineralization, 1124
- I**
- Imaging, 532, 545–546
 biomarker, 562, 572–581
- Immunoassay, 132
 electrochemiluminescence, 130, 141
 PTH, methods, 138–144
 PTH modifications and, 143–144
 radioimmunoassay, 131
 second generation, 139
 third generation, 139–141
- Inflammation, 258–259
- Intact PTH (iPTH), 132, 139, 144
- Integrin alpha2beta1 ($\alpha 2 \beta 1$), 490
 as cancer biomarker, 491–492
 cancer stem/tumor initiating cells, 491
 collagen type, 493–495
 directed metastasis, 497
 metastasis suppressor in BrCa, 495–496
 PCa skeletal metastasis, 492–493
 therapeutic targeting in cancer, 499–500
 tumor dormancy acquisition, 497–498
- Integrins, premetastatic niche formation, 499
- Intrauterine growth restriction (IUGR), bone
 turnover markers in, 787–790
- Isoflavone, 1143–1145
- J**
- Journals, 1174
- L**
- LRP4 receptor, 232
- M**
- Macrophages, 306, 308, 309, 312, 314, 315, 318
- Magnetic resonance imaging (MRI), 534, 539,
 540, 543
- Mandibular cortical index, 514–519
- Markers
 bone, 50, 65
 bone loss, 51
 of bone formation, 50, 61, 65
 urinary, 54
- Mass spectrometry, 833–834, 839
- Mechanical loading, 626–629, 638–640
- Medicinal plants, 50, 53, 63, 65
- Mental index (MI), 519–521
- Mesenchymal stem cells
 in osteoarthritis, 165–166
 recruitment and differentiation, 161–162
- Metabolic bone disease
 monitoring, QUS, 709–712
 morbidities and screening, 707–708
 of prematurity, 803, 806, 808, 812
 in preterm infants, 702–706
- Metastasis, 496–497
- Methyl-CPG-binding protein 2 (MECP2), 725
- Microarray, 476, 478
- Micro-computed tomography (microCT), 562
 bone, 567–572
- MicroRNAs (miRNAs)
 circulating miRNAs, 30, 31
 detection methods, 29
 in osteosarcoma, 28–29
- Mineral
 content, bone, 803
 deficiency, 808
 supplementation, 808
 transport, 803
- Mineralization, 682
- miRNAs. *See* MicroRNAs (miRNAs)
- Modeling bone, 78, 562, 563
- Molecular genetics, 186
- Monocytes, 306, 318
- Mortality, and hip fractures, 1159, 1163, 1164
- N**
- Natural alpha radioactivity, 111
- Neck shaft angle (NSA), 633, 635
- Neonate, bone turnover markers, 786–787
- Neonatology, 703, 707
- Non-enzymatic collagen crosslinks, 362
- N-terminal propeptides of collagen type
 I (P1NP), 729
- Nutrition
 parenteral, 808, 811
 preterm, 810
 type of, 809
- O**
- Obesity, 740, 743
- Omics approaches
 biomarkers discovery, 27
 mMicroRNAs, 27–30

- proteomics, 34–40
 - transcriptomics, 30–34
 - Orchidectomy, 1140
 - Osteoarthritis (OA), 163–166
 - bone markers, 1013
 - collagen biomarkers, 999–1009
 - description, 532, 834
 - glycoblotting (*see* Glycoblotting method)
 - markers specific for, 835–836
 - non-collagenous biomarkers, 1009–1013
 - pathology, 996
 - potential applications of biomarkers, 839–843
 - protein biomarker, 836–839
 - proteomics, 839–843
 - role of bone, 996
 - subchondral bone (*see* Subchondral bone)
 - Osteoblasts, 187, 190, 257, 258, 271, 272, 287, 290, 305, 306, 308, 309, 316, 332, 333, 338, 1110, 1117, 1121, 1122, 1124, 1136, 1138
 - Osteocalcin, 245, 729, 937, 1031
 - characteristics, 243–244
 - reference values, 244–245
 - utilisation, 244
 - Osteoclast(s), 185, 187, 188, 192, 258, 259, 306, 308, 309, 311, 314, 316, 318, 332, 334, 341, 432, 468–471, 1110, 1111, 1121, 1124, 1136, 1138
 - Osteogenesis, 865, 870
 - Osteogenesis imperfecta, 179, 673
 - applications, 194–196
 - biomarkers, 1094–1096
 - characteristics and classification, 1093–1094
 - CKbb, 190–194
 - classification, 186
 - diagnosis, 188
 - molecular genetics, 186
 - pathogenesis, 187
 - serum sclerostin levels, 1096–1097
 - treatment, 188–190
 - type I collagen, 185
 - Osteonectin, 1030–1031
 - Osteopenia
 - and monitoring supplementation, 805–808
 - of prematurity, 802
 - prognosis of, 814–815
 - Osteopetrosis
 - ADO II, 472–475, 481
 - CLCN7, 471–472
 - osteoclast(s), 468–471, 476
 - Osteopontin, 1029–1030
 - Osteoporosis, 50, 52, 55, 167–170, 210, 214, 216, 365, 511–513, 604, 606, 614, 615, 673, 681, 772–775, 785, 790, 853, 907, 917, 922–927, 962
 - adiponectin effects in, 861–862
 - adiponectin levels, 868–875
 - causes, 1080
 - colon cancer, 402
 - definition, 962, 1070
 - glucocorticoids, 986
 - gonadal hormones, 984
 - insulin resistance, 984
 - leptin, 985
 - management, 1072
 - pathogenesis, 972, 987
 - in postmenopausal women, 986
 - therapies, 1078
 - Osteoprotegerin, 1030
 - Osteosarcoma
 - biomarkers, 40
 - genome-wide and microarray studies, 32
 - miRNAs expression, 28–29
 - Ovariectomy, 1138–1142
 - Oxidative stress, 206–207, 409, 411–412
- P**
- Paget's disease
 - alkaline phosphate, 890–898
 - description, 885
 - and genetic mutations, 898–899
 - prevalence, 885
 - severity, 886–889
 - Panoramic mandibular index, 515, 521–524
 - Panoramic radiographs, 513, 514–515
 - Parathyroid hormone (PTH), 129, 131
 - applications, 456
 - assays, evolution of, 132–134
 - biological modifications, 129
 - in bone, 449
 - immunoassays, methods, 138–144
 - in intestine, 448–449
 - in kidney, 448
 - phosphorus and FGF23, 455
 - pre-analytical factors, 134–138
 - RANKL:OPG, 450–452
 - sclerostin, 452–454
 - structure, 144
 - structure and physiology, 445–448
 - vitamin D, 454
 - Pentosidine, 362, 367–382

- Pentraxin 3 (PTX3)
 aggressive periodontitis, 258
 bone cells, 257
 bone metastatic cancer, 260
 cellular sources, 257
 inflammatory condition of bone resorption,
 258–259
 physiological bone formation, 258
- Phosphorus (P), 802
- Post-genomics, 40
- Postmenopause, 1142–1144
- Pre-eclampsia, 822, 823
- Pregnancy-induced hypertension, 821
 biochemical markers, 823–827
 bone mineral density, 822–823
- Premature infants, 812
 metabolic bone disease in, 702–706
- Primary hyperparathyroidism, 140, 144–148
- Procollagen type I N-propeptide (PINP), 248,
 249, 938
 characteristics, 245
 reference values, 247
 utilisation, 247
- Professional societies, 1174
- Prostate cancer, 400, 491
- Proteomics, 34–40, 839–843
- Q**
- Quantitative computed tomography (QCT),
 630, 632, 639–640
- Quantitative ultrasound (QUS), metabolic bone
 disease, 709–712
- R**
- Radiomorphometric Indices, 515
- Raman spectroscopy
 assignments, 680–681
 biomechanical properties and mechanical
 testing, 693
 experimental preparation, 678–679
 preprocessing, 679
 principle and technological solutions,
 676–678
- RANKL, 258, 259
 OPG, 450–452
- Reference values
 osteocalcin, 244–245
 procollagen type I N-propeptide, 247
- Registry, 1158, 1164
- Regulatory bodies, 1173
- Relaxin (RLN), 331, 333, 334, 341
- Relaxin family peptide receptor (RXFP), 334,
 342
- Remodeling, 78
 bone, 562–564, 578, 579
 methods of assessing bone, 564–567
- Renal osteodystrophy, 133, 146
- Resorption, 997, 1000, 1001
- Resources, 1173, 1176
- Rett syndrome (RTT)
 biochemical bone marker, 727–733
 bone development, 725
 bone formation markers, 728
 bone resorption marker, 728
 revised diagnostic criteria, 726
 symptoms progression, 727
- Rickets, of prematurity, 803
- S**
- Sclerosing bone disorders, 229–233
- Sclerosing bone dysplasia, 232
- Sclerosteosis, 229
- Sclerostin
 assays, 225–228
 and bisphosphonate treatment, 1099
 bone mineral density and bone
 microstructure, 1097–1099
 and bone turnover markers, 1099
 circulating sclerostin, 229–233
 description, 1091
 and fracture risk, 1100
 genetics and proteomics, 1092–1093
 molecule and actions, 223–224
 serum level in adults, 1096–1097
 serum level in children, 1096
- Secular trends, 896, 897
- Sexual development
 EPITeen cohort study, 88
 formation markers, 85–87
 resorption markers, 81
 resorption markers, 81–82
- Sirtuins
 applications, 170
 biochemical reaction, 160
 in bone homeostasis, 162–163
 classes, 160
 in mesenchymal stem cell recruitment and
 differentiation, 161–162
 in osteoarthritis, 163–166
 in osteoporosis, 167–170
- Site-specificity of bone physiopathology, 272,
 288
- Skeletal metastasis, 492–493

- Smokers, 106, 116
Soy isoflavone, 1135, 1143–1146
Spinal cord injury
 bone turnover after (*see* Bone turnover)
 causes, 962
 description, 961
Spot urine, 808, 811
SQSTM1 protein, 898–899
Statins, 938–939
 aminobisphosphonates and, 939
 and BTMs, 940
Subchondral bone, 997, 998
 attrition, 534
 bone marrow density, 536–539
 bone marrow lesions, 535
 bone volume fraction, 539–540
 cysts, 540
 description, 533
 mechanics, 544–548
 osteophytes, 541
 shape, 542
 texture, 542–543
Supplementation
 Ca and P, 805
 mineral, 805, 806
Surgery, hip fracture and, 1159, 1163, 1165
Synovial fluid, 834, 840, 843
Synovium, 834, 836
- T**
Tartarate resistant acid phosphatase (TRACP)
 acid phosphatase enzymatic activity, 427
 applications, 436
 bone pathologies, 431
 expression and location, 426
 isoforms, 427
 monitoring anti-resorptive treatment: 435
 osteoblast regulation, 431
 osteoclastic bone resorption, 428–431
 reactive oxygen species generation, 428
 structure, 425–426
TECO sclerostin assay, 226
Teeth, 110, 111
Telopeptide, 920
- Trabecular bone score (TBS)
 clinical correlates, 596
 clinical practice guidelines, 608–610
 conceptual aspects of, 590–592
 cross sectional studies, 597–600
 diabetes mellitus, 611–612
 fracture risk prediction, 605–608
 glucocorticoid exposure, 612–613
 in vitro validation studies, 593–595
 in vivo validation studies, 595–596
 longitudinal studies, 597–600
 monitoring and treatment responsiveness,
 614–616
 technical aspects of, 592–593
TRACP 5a, 432
TRACP 5b, 432
Traditional medicine, 50, 64
Transcriptomics, 30–34
Treatment failure, 1068, 1079
Turnover, 1000
- U**
Uric acid
 and bone fracture, 208, 213–215
 with bone mineral density, 207–213
 pro-oxidant/antioxidant, 204–206
- V**
Van Buchem disease, 231
Vitamin D
 chronic diseases, deficiency in, 401–402
 diagnosis of mild vitamin D deficiency,
 398–399
 mineral metabolism, role in, 396–397
 non-skeletal tissues, effects on, 399–400
 parathyroid hormone, 454
 synthesis and biological actions, 395–396
- W**
Wnt/ β -catenin, 162, 164
Wnt-pathway, 1091